Ilixadencel – an Allogeneic Cell-Based Anticancer Immune Primer for Intratumoral Administration
Time: 3:30 pm
day: Day Two
Details:
- Proposed mode of action
- Preclinical in vivo data in combination with anti-VEGF antibodies and checkpoint inhibitors
- Clinical data from a randomized phase 2 study in mRCC in combination with sunitinib (VEGFR-TKI) leading to Regenerative Medicine Advanced Therapy Designation by FDA
